SML0288
Nepafenac
≥98% (HPLC)
Synonym(s):
2-Amino-3-benzoyl-benzeneacetamide, AHR 9434, AL 6515
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C15H14N2O2
CAS Number:
Molecular Weight:
254.28
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
Quality Level
assay
≥98% (HPLC)
form
powder
color
faintly yellow to dark yellow
solubility
DMSO: ≥5 mg/mL
storage temp.
room temp
SMILES string
NC(=O)Cc1cccc(c1N)C(=O)c2ccccc2
InChI
1S/C15H14N2O2/c16-13(18)9-11-7-4-8-12(14(11)17)15(19)10-5-2-1-3-6-10/h1-8H,9,17H2,(H2,16,18)
InChI key
QEFAQIPZVLVERP-UHFFFAOYSA-N
Gene Information
human ... PTGS1(5742), PTGS2(5743)
Biochem/physiol Actions
Nepafenac, a prodrug of amfenac, is used in the treatment of diabetic retinopathy. It is metabolized to its active form through intraocular enzymatic hydrolysis. Nepafenac has a molecular weight of 254.28 kDa and effectively penetrates through the cornea. Its molecule structure enables nepafenac to possess better permeability. Nepafenac has a low inhibitory effect on cyclooxygenase.
Nepafenac is a NSAID (nonsteroidal anti inflammatory drug) that is routinely used in opthamology to control pain following cataract surgery.
Nepafenac is a NSAID (nonsteroidal anti inflammatory drug) used in opthamology.
Still not finding the right product?
Explore all of our products under Nepafenac
signalword
Warning
hcodes
pcodes
Hazard Classifications
Aquatic Acute 1 - Aquatic Chronic 1
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Retinal Pharmacotherapeutics: Retinal Pharmacotherapeutics (2015)
Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology
Kern TS, et al.
Diabetes, 56(2), 373-379 (2007)
Eric Chen et al.
Clinical ophthalmology (Auckland, N.Z.), 4, 1249-1252 (2010-12-15)
The purpose of this study is to determine the efficacy of combining topical nepafenac with monthly intravitreal injections of ranibizumab or bevacizumab in the treatment of recalcitrant exudative macular degeneration. This was a retrospective, consecutive case series of patients with
Global Trade Item Number
| SKU | GTIN |
|---|---|
| SML0288-10MG | 04061837084119 |
| SML0288-50MG | 04061832786452 |